Prof. Joseph V. Pergolizzi

Department of Medicine

Johns Hopkins University School of Medicine, USA

Adjunct Assistant Professor



1997 Post-Doc Fellowship, Clin. Res., Johns Hopkins University School of Medicine,

1996 M.D., Medical Doctorate, Ross University School of Medicine

1989 B.Sc., Physical Chemistry, St. Johns University

Publications (Selected)

  1. Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S,  Ben-Joseph R and Summers KH. Exposure to Potential CYP450 Pharmacokinetic Drug–Drug Interactions among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions. Pain Practice Article first published online : 28 DEC 2010, DOI: 10.1111/j.1533-2500.2010.00438.x
  2. Pergolizzi J, Labhsetwar S,  Puenpatom A, Joo S,  Ben-Joseph R, Summers K. Prevalence of Exposure to Potential CYP450 Pharmacokinetic Drug0Drug Interactions among Patients with Chronic Low Back Pain Taking Opioids. Pain Practice Article first published online: 26 AUG 2010 DOI: 10.1111/j.1533-2500.2010.00413.x
  3. Pergolizzi J, Boger R, Budd K,  Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa R, Sacerdote P. Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone. Pain Practice June 2008.
  4. Pergolizzi J, Raffa, R, and  Goul, E.  Considerations on the use of oxymorphone in geriatric patients Expert Opin. Drug Saf. (2009) 8(5)
  5. Varrassi‌ G, Müller-Schwefe‌ , Pergolizzi J‌,  Orónska A, Morlion B, Mavrocordatos‌ Margarit C, Mangas‌ , Jaksch W,  Huygen‌ , Collett B, Berti M‌l, Aldington‌, Ahlbeck K. Pharmacological treatment of chronic pain – the need for CHANGE Current Medical Research and Opinion 2010: 26(5): 1231-1245
  6. Pergolizzi J, Mercadante S, Virizuela Echaburuc A,  Van den Eyndend B, de Farı´a Fragosoe RM, Mordarskif S, Lybaertg W, Beniakh J, Oron´ skai A, and Slamaj O. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus. Current Medical Research and Opinion  25:6:  2009, 1517–1528
  7. Pergolizzi J, Pappagallo M, Stauffer J, Gharibo C, Fortner N, De Jesus MN, Brennan MJ, Richmond C, Hussey D; The Integrated Drug Compliance Study Group (IDCSG).  The Role of Urine Drug Testing for Patients on Opioid Therapy. Pain Pract. 2010 Nov;10(6):497-507.
  8. Arbuck D, Gharibo C, Labhsetwar S,  Berdos F, Pergolizzi J. Management of Opioid Tolerability and Related Adverse Effects.  Journal of Medicine 2010; 3(1):1–10
  9. Hochman JS, Pergolizzi J. Cohort study finds nine times increased overdose risk (fatal plus non-fatal) in patients receiving 100 mg/day for 90 days compared with 1-20 mg/day opioids for chronic non-cancer pain, but wide CI and possibility of unmeasured confounders. Evid Based Nurs. 2010 Apr;13(2):55-6.